Introduction: A paradigm shift in breast cancer was introduced by Sørlie's concept of intrinsic subtypes [1] . We validated this concept e which was originally based on 84 individuals e in a large cohort study of 1035 patients with oncoplastic surgery and analyzed if early and late recurrences are linked to a specific intrinsic tumor subtype or resection margins. Materials and methods: 1035 patients with oncoplastic surgery (2004e2009) were analyzed with regard to treatment characteristics and patterns of early (<5 years) and late recurrence (>5 years) and survival related to the intrinsic subtypes. Data was retrieved from patient's charts, customized patients questionnaires and cancer registries. Results: 944 patients with primary, unilateral breast cancer, median age 58 years, were eligible for analysis. At a median FU of 5.2 years, LRR was 4.0%, 5-year-OS 94.5% and DFS 90.9%. Intrinsic subtypes, but not T-size, nodal-status, resections margins nor histopathology, governed local control and survival. There was no signal for prevelance of unclear margins in any of intrinsic subgroups and no preference of any oncoplastic technique attributed to them. TNBC and Her2 non-luminal breast cancer had highest recurrence and lowest survival rates. Although sentinel involvement (SLNþ) was prevailing in the Luminal-B-Her 2 negative subtype at 34.3%, this did not translate into a higher axillary dissection rate. Conclusion: This study confirmed the intrinsic subtype concept on a large clinical basis and describes the patterns of early and late recurrence in oncoplastic surgery, concluding that bigger risk may not be overcome by bigger surgery.
Introduction
Various oncoplastic techniques have evolved in the last decades and former concepts attributed high oncologic safety to a high extent of surgery in breast cancer (BC). Determinants of local control were mainly considered to be T-size, resection margins and nodal status until the intrinsic subtype concept by Sorlie T. et al. in 2001 has been introduced [1] . In this study, we investigated different surgical techniques in relation to intrinsic subtypes, as each of these subtypes yields different recurrence rates. This may lead to surgeons' assumption that also clinicopathological features of these subtypes may vary in the sense of higher occurence of multicentricity, presence of unclear margins, re-excision rate and nodal involvement. Surgeons may be tempted to try to overcome "bigger risk" by applying "bigger surgery" [2] , with a predilection for bigger margins or mastectomy in highrisk intrinsic subtypes. The question remained whether recurrences occur due to intrinsic biology and/or unclear margins and whether tumor biology may be overturned by applying extensive surgery as postulated by the Halstedian dogma in the last century. Sorlie's milestone paper was originally based on a cohort of 84 patients [1] . We translated this concept into a cohort of more than 1000 oncoplastic patients in order to analyze whether this concept may be confirmed in the framework of oncoplastic techniques and if oncoplastic breast conserving techniques are valid options for dealing with all intrinsic subtypes at a high degree of local and systemic control. We assessed recurrence rates (early: <5 years, late: > 5 years), DFS and OS and related it to intrinsic subtypes, grading, T-size, nodal-status, resection margins and histopathological subtypes.
Patients and methods

Patient cohort
A total of 1035 patients with BC and oncoplastic surgery from 2004 to 2009 were identified for this study. Inclusion criteria were unilateral, non-metastasized primary BC and 944 patients finally fulfilled these criteria. Patient and treatment characteristics as well as survival data were retrieved from patient records, customized questionnaires and cancer registries. The study was approved by the institutional review board and complied with the declarations of Helsinki and the principles of good clinical practice.
Tumor classification
Tumors were classified according to TNM-system [3] and analyzed in a central pathology. Grading was classified according to Elston and Ellis [4] . ER and PR status of BC specimen included in our study were considered as positive if !10% of BC cells expressed ER and/or PR, in accordance with the AGO and ASCO/CAP guidelines at the time of patient enrollment for treatment [5, 6] . Her2-status was considered as positive if DAKO-Score was 3þ or FISH-analysis was positive in DAKO-Score 2þ [6] .
As [7] .
Statistics
Data was entered into a Microsoft Office Excel 2007 database, and analyses were performed using SAS Version 9.2. Local control parameters were calculated in a univariate and multiple analysis. All patient characteristics were presented in frequency tables and compared by univariate testing (Wilcoxon rank sum and chisquare tests). Patient numbers refer to a total of 944; calculating percentages includes missings. Survival was estimated and plotted by using KaplaneMeier analysis. Log-rank test and Wilcoxon-rank sum tests were used. Multiple Cox proportional hazards regression models were used for estimating age-adjusted hazard ratios (HR) with 95% confidence intervals (95% CI). All pvalues were given descriptively without further adjustment for multiple testing.
Results
Patients baseline characteristics
A total of 944 patients met inclusion criteria. 70.7% was the questionnaire response rate. Median follow-up was 5.2 years.
Average age was 57.6 years (median 58, range 25e88 years) ( Table 1) .
Tumor localisation
The most common tumor localization was the upper outer quadrant with 36.5% (Fig. 1.) , 11.7% were multifocal or multicentric. 
Tumor histology and receptor subtype
Invasive BC was the most common histology (þ/À non-invasive component): 60.6% invasive-ductal BC, 11.6% invasive-lobular (ILC) and 9.4% invasive-tubulo-ductal (ITD) or lobular-ductal (LDC). Only 11.7% (n ¼ 110) have been classified as non-invasive BC with 95.5% as DCIS and 2.7% as CLIS. Hormone receptor (HR) was positive in 82.5% and Her2-receptor in 14.2%. Luminal A was the predominant subtype (62.6%). Fig. 2 displays the distribution of approximated intrinsic subtypes.
Tumor and treatment characteristics of intrinsic subgroups
Although the rate of sentinel involvement (SLNþ) was highest in the Luminal B Her 2 negative subtype at 34.3%, this was not reflected in a higher axillary dissection rate which was at 23.3% comparable to all other subtypes. As we determined intrinsic subtypes along histopathological approximation and used grading as a tool according to St. Gallen 2011 guidelines, only the distribution of grading in TNBC and Her2 subtypes are reported here. We found grade 3 in TNBC with 54.6% and in Her2 non luminal subtype with 66.7%. In Luminal B Her2 positive 56.3% were grade 2 and 32.5% grade 3 (p < 0.0001). There was no signal of overrepresentation of any subtype in the group of tumors with unclear margins (n ¼ 108). The majority (89.8%) opted for re-excision e only 14 cases remained with unclear margins (1.5% of whole cohort).
T-size at diagnosis varied within the intrinsic subtype groups with Luminal B Her2 negative at greatest tumor size. We did not detect any differences in type of surgery related to intrinsic subtypes.
TNBC occurred more often in younger women aged <40 years with 21.0% compared with older patients (50e59 years 10% and 60e69 years 8%). Frequency of Luminal A increased with age: 73% were older than 70 years old versus 38% aged <40 years (p ¼ 0.008).
Treatment characteristics Surgery
Glandular rotation mammaplasty (63.8%) and tumor-siteadapted reduction mammaplasty (20.9%) were the most frequent oncoplastic techniques (Fig. 3) . The median resection volume was 32 g (range 11e793 g). A secondary mastectomy as subsequent surgery was necessary only in 7.2% (multicentricity, extensive tumor size or repeatedly unclear margins).
Systemic therapy
Information on chemotherapy was available in 76.1%, out of which 25.3% underwent adjuvant chemotherapy, 20.2% neoadjuvant chemotherapy and 3.5% both of them. Endocrine therapy was prescribed for all ERþ/PR þ cases and continued by 62.2%.
Patterns of recurrence e LRR, DFS and OS according to tumor biology and type of surgery
At a median follow-up of 5.2 years, 38 out of 944 patients (4.0%; 95% CI 2.8%e5.5%) had a local recurrence (range 0.1e8.6 years); most of them (n ¼ 34) in the first 5 years after diagnosis, only in 4 cases the recurrence appeared after a follow-up of 5 years. At 5 years, DFS was 90.9% and OS 94.5% (see Table 2 ).
TNBC had highest LRR (11.3%) followed by Her2 non-luminal subtype with 9.3%. Recurrences occurred in lateral thoracic wall advancement at 7.1%, glandular rotation mammaplasty at 3.8%, dermoglandular rotation mammaplasty at 4.8% and tumor-adapted reduction mammaplasty at 3.6%. However, there was no significant difference in recurrence rates as to the type of oncoplastic surgery. (p ¼ n.s.).
Age and recurrence
Recurrence rates and survival did not vary significantly with age: patients aged < 40 years experienced a local recurrence with a rate of 8.3% (95%CI 2.3%e20%) compared with patients aged ! 40 years at 3.8% (95%CI 2.7%-5.4%, (p > 0.05)). OS was 95.3% vs. 94.5% (p > 0.05), and 5 y-DFS was 92.7% vs. 95.9% (p > 0.05) (see Fig. 4 ).
T-size
The recurrence of non-invasive BC was 6.4% versus 3.7% in invasive BC (p ¼ 0.17). Recurrence rate of pT1a-tumors was 7.1%. Of note, all recurrences in this group were associated with high grade, triple-negative and Her2 non-luminal breast cancer. DFS and OS was: T1a 92.9% and 100%, T1b 94.4% and 95.3%, T1c 91.8% and 95.2%, T2 87.3% and 91.9%. Low representation of Tmic, T3 and T4 cases did not allow statistical comparison of these groups. Tumor size did not have a significant impact on LRR (p ¼ 0.12) or survival (p > 0.05) in this cohort of predominantly T1/T2 tumors. 
Nodal-status
Nodal negative disease (N0) and low lymphatic involvement (N1) did not yield significant differences in LRR (
In nodal stage N2a, we detected a significant lower OS compared to N0 (81.5% versus 95.7%; p < 0.05). This did not apply to DFS because there was no local recurrence in the group of N2a. In N3a, 2 of 10 patients experienced a local recurrence. OS was 90.0%, DFS 70.0% in this group (Table 3) .
Grading
Recurrence rates and mortality rates differed significantly. G3-tumors had a significantly lower survival compared with grade 2 or grade 1 (p < 0.01). 5-years OS was 90.2% for G3, 95.1% for G2 and 100% for G1 (p < 0.01), DFS was 84.2% for G3, 91.9% for G2 and 100% for G1 (p < 0.001). LRR was incremental with grading: 1.0% for G1-tumors, 3.5% for G2 and 7.0% for G3 (p < 0.01). Multivariate analysis demonstrated that G3 was significantly associated with lower survival rates (DFS p < 0.01; OS p < 0.01) (see Fig. 5 ). Fig. 6 ).
Histopathology
Resection margins
All recurrences in our cohort were in cases of surgery with clear margins (38/910; LRR 4.2%). We identified 14 resections with unclear margins. There was no significant difference in OS and DFS in both groups (OS R0 94.6% vs. 90.3%; p > 0.05; DFS R0 94.4% vs R1 100%; p ¼ 0.4). In 20 cases there was no information on further resection of unclear margins. Factors included in multivariate regression analysis are compiled in Table 4 (supplement.material).
Discussion
The median age of our cohort of 944 primary unilateral BC was at 57.6 years approximately 7.5 years lower than generally in Germany [8] . Although in the present study there were no significant differences in local recurrence rates, DFS and OS between the age groups of <40 years and over !40 years, in several studies age has been confirmed as an independent prognostic factor. Miles R. et al. (2012) found a lower 5 year-RFS (recurrence-free-survival) in patients < 40 years compared with patients ! 40 years (p < 0.01), but not a lower OS. Han W. and also other study groups found a cutoff at 35 years for age as an independent risk factor in breast BC [9e12] with significant lower DFS and OS. LoiblS. et al. also described higher LRR after neoadjuvant chemotherapy with a cutoff at 35 years, but not a lower mortality rate [13] . 
Fig. 4. Recurrence rate according to age groups: exact 95% confidence interval around proportion. In this study, we found the highest LRR among non-invasive tumors (6.4%). The LRR increased gradually in our cohort of predominantly T1 and T2-tumors with the extent of tumor size, however this did not achieve statistical significance (T1b 1.8%, T1c 3.6%, T2 4.3%). Surprisingly, we identified a high recurrence rate of 7.1% in pT1a (2/28 pts.) tumors. Both recurrences originated from G3 and triple-negative BC, respectively Her2 non luminal tumors. Nevertheless, the 5year-OS of pTis and pT1a was still high with 98% and 100%.
Unlike the findings in our study, Rausei S. et al. found a reduced OS with increasing tumor size (5-year-OS T0-T1 99.0% versus T3 85.4% and T4 86.9%, p < 0.001) [14] . Botteri E. et al. showed that risk of distant metastases and mortality increased with tumor size (p < 0.01) [15] . Wapnir IL.et al. reported from 5-NSABP node positive adjuvant BC trials that tumor size over 2.1 cm represents a higher risk for in-breast-true recurrence (IBTR) [16] .
The nodal status is a recognized prognostic factor. According to Hernandez-Aya L.F. et al., OS and RFS significantly decreased with extent of lymph node involvement. In pairwise comparison, only N2/N3 showed a significant worse survival compared with N0, contrary to N1 versus N0 where no differences were detected [17] . This corresponds well with the findings in our study.
Grading has already been confirmed early as significant prognostic factor [17, 18] . After histopathological approximation of intrinsic subtypes according to 2011 St. Gallen criteria [6] , we explored recurrences in our cohort and found them to correspond with the cohort of intrinsic subtypes of Sørlie et al. (2001) [1] . TNBC in our cohort had a higher recurrence (LRR 11.3%) compared with those published by Hattangadi-Gluth J. et al. (2012) [19] , with LRR in a similar cohort with T1-T2/N0-3 tumors and 5-y-FU of Luminal A 0.2%, Her2 9.0%, basal-like (triple-negative) 4.4% (p < 0.0001) [20] . TNBC had a markedly lower survival rate. Wang Y et al. (2011) had similar results in their study. We also confirmed this in a previous study of a large cancer registry [21] .
Of note, Luminal B HER2 negative BC had a trend to lower survival in our cohort compared with international data. This may be explained by the uniform poor differentiation (G3) in this subgroup.
There was no signal of over-representation of any intrinsic subtype in the group of tumors with unclear margins (n ¼ 108). We found that intrinsic subtype is not a predictor for unclear margins (p > 0.05). This issue has not been specifically addressed before in international literature, whereas some studies have put emphasis on the fact that intrinsic subtypes are prognostic for nodal involvement or other histopathological features as Jones T et al. have published in a case cohort study (2013) [22] .
This study encourages surgeons to breast conservation because it shows that type of oncoplastic surgery does not need to vary with intrinsic subtypes as all intrinsic subtypes may be dealt with breast preservation at a high level of local oncological safety. Specific BC subtypes do not bear a higher risk of recurrence due to their multicentricity or other clinico-pathological features like tumor size at diagnosis or nodal involvement but due to their early systemic spread and local recurrence even after mastectomy.
The histological subtypes e invasive-ductal and lobular e did not exert any impact on different local control or survival. Arpino [24] . With regard to the patient population, the Korean cohort published by Lee J.-H. et al., our subgroup of ILC included more HR positive and Her2 enriched tumors [24] . Arpino G. et al. and Pestalozzi B.C et al., had older patients with ILC, the tumors were larger than the IDC and had a higher grading [23, 25] . In our study population, there were no differences in the representation of ILC in the age groups, intrinsic subgroups, different tumor sizes and nodal status. As to the grading, the IDC had more G3-tumors with 23.0% compared with ILC (2.7%).Clearness of margins did not convey a substantial survival benefit under multimodal treatment in our study. Lobular histology was not associated with a higher rate of unclear margins, recurrence or mortality than invasive-ductal histology. Whereas increasing T-size did not correlate with an inferior survival, tumor biology according to intrinsic subtypes was governing the fate of the local control of the study population. In this study, the majority of patients presented with T1/T2 stages, which reflects the situation of modern, early detection of breast cancer.
Conclusion
This study of more than 1000 oncoplastic patients may serve as a translation of the concept of intrinsic subtypes into the framework of oncoplastic surgery, and furthermore deciphers the following principles relevant for oncoplastic surgery: T1 and T2 tumor stages do not differ significantly in prognosis and low lymph node involvement is comparable to no lymph node involvement. Type of oncoplastic surgery does not vary with intrinsic subtype. Lobular histology and multifocal/multicentric DCIS are predictors of secondary mastectomy, but do not convey any impact on overall survival. Local recurrences are a variable of intrinsic subtypes with triple negative breast cancer and non luminal Her2 enriched breast cancer at highest risk of recurrence. A larger extent of surgery may not overcome a higher intrinsic risk. Multimodal treatment and oncoplastic surgery with resections of a median of 32 g in a cohort of predominantly T1/T2-tumors provides a high level of local control and survival.
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